Citations

Mayo Clinic

Showing 10 of 108551 citations.

IgG4‐Related Disease: Retrospective Analysis of One Hundred Sixty‐Six Patients
Sekiguchi, Hiroshi , Horie, Ryohei , Kanai, Mio, Suzuki, Reina , Yi, Eunhee S. , Ryu, Jay H. , Ryu, Jay H

Arthritis & Rheumatology | March 19, 2016 | Volume: 68 | Issue: 9 | Pages: 2290-2299

10.1002/art.39686 | PMID 26990055 Get It

ObjectiveTo investigate clinical and pathologic aspects of IgG4‐related disease (IgG4‐RD) in non‐Asian populations.MethodsWe conducted a retrospective review of the medical records of patients with IgG4‐RD who presented to an academic medical center from January 1994 to September 2012.ResultsAmong 166 patients identified, the median age at diagnosis was 61 years (interquartile range [IQR] 49–70 years), 75% were male, and 80% were white. The median number of organs involved was 2 (IQR 2–3). When organs were grouped according to anatomic system, the hepatopancreaticobiliary system was most commonly involved (77%). The median highest serum IgG4 level during the clinical course was 215 mg/dl (IQR 122–466). Forty‐three patients (26%) had a normal serum IgG4 level. Seventy‐nine pathology specimens were available for immunostaining. The median number of IgG4+ cells was 37 (IQR 25–82) per high‐power field, with an IgG4+:IgG+ ratio of 0.50 (IQR 0.32–0.68). Among 151 patients who received medical therapy, 72 (48%) received steroid‐sparing agents because of relapse, recurrence, or corticosteroid intolerance. Of the 66 patients who were newly diagnosed, started on corticosteroid monotherapy as the initial treatment, and followed up at our institution, 30 (45%) experienced relapse or recurrence despite an initial favorable response. The number of organs involved had a significant impact on time to relapse or recurrence, with a hazard ratio of 1.48 (95% confidence interval [95% CI] 1.12–1.93) (P < 0.01) in multivariate analysis. The standardized incidence ratio of malignancy was 4.5 (95% CI 1.5–7.5).Conclusion. IgG4‐RD is a multisystem disorder that commonly affects older men and has a propensity for relapse, recurrence, and malignancy.
Sequential early and delayed painful sciatic neuropathy following revision total hip arthroplasty
Desy, Nicholas M. , Spinner, Robert J. , Amrami, Kimberly K. , Lewallen, David G.

Clinical Anatomy | March 19, 2016 | Volume: 29 | Issue: 6 | Pages: 804-806

10.1002/ca.22713 | PMID 26990207 Get It

Combining existing numerical models with data assimilation using weighted least‐squares finite element methods
Rajaraman, Prathish K. , Manteuffel, Thomas A. , Bëlohlávek, Marek , Heys, Jeffrey J.

International Journal for Numerical Methods in Biomedical Engineering | March 19, 2016 | Volume: 33 | Issue: 1 | Pages: No page available

10.1002/cnm.2783 | PMID 26991079 Get It

SummaryA new approach has been developed for combining and enhancing the results from an existing computational fluid dynamics model with experimental data using the weighted least‐squares finite element method (WLSFEM). Development of the approach was motivated by the existence of both limited experimental blood velocity in the left ventricle and inexact numerical models of the same flow. Limitations of the experimental data include measurement noise and having data only along a two‐dimensional plane. Most numerical modeling approaches do not provide the flexibility to assimilate noisy experimental data. We previously developed an approach that could assimilate experimental data into the process of numerically solving the Navier–Stokes equations, but the approach was limited because it required the use of specific finite element methods for solving all model equations and did not support alternative numerical approximation methods. The new approach presented here allows virtually any numerical method to be used for approximately solving the Navier–Stokes equations, and then the WLSFEM is used to combine the experimental data with the numerical solution of the model equations in a final step. The approach dynamically adjusts the influence of the experimental data on the numerical solution so that more accurate data are more closely matched by the final solution and less accurate data are not closely matched. The new approach is demonstrated on different test problems and provides significantly reduced computational costs compared with many previous methods for data assimilation. Copyright © 2016 John Wiley & Sons, Ltd.
Standardized terminology and nomenclature for respiratory cytology: The Papanicolaou Society of Cytopathology guidelines
Elsheikh, Tarik M. , Litzky, Leslie A., Rektman, Natasha, Travis, William D. , Zakowski, Maureen F. , Zarka, Matthew A., Geisinger, Kim R., Zarka, Matthew, Layfield, Lester James , Baloch, Zubair , Travis, William D

Diagnostic Cytopathology | March 19, 2016 | Volume: 44 | Issue: 5 | Pages: 399-409

10.1002/dc.23457 | PMID 26990836 Get It

BackgroundThe Papanicolaou Society of Cytopathology has developed a set of guidelines for respiratory cytology including indications for cytologic testing, techniques for cytologic sampling, terminology and nomenclature for respiratory diseases, ancillary testing, and recommendations for postcytologic diagnosis follow‐up and management.MethodsAll documents are based on the expertise of the authors, an extensive literature review and discussions of the draft documents at national and international meetings over a 12‐month period. This document selectively presents the results of these discussions and reports a proposed standardized terminology scheme for respiratory cytology that correlates cytologic diagnosis with biologic behavior and patient management.ResultsThe classification and terminology scheme recommends a six‐tiered system composed of: nondiagnostic, negative, atypical, neoplastic (benign and neoplasms of low malignant potential), suspicious, and positive for malignancy.ConclusionThe scheme recommends statements on specimen adequacy followed by the major classification category and then a subclassification and/or comments section. Each of the six main diagnostic categories is associated with an estimated risk of malignancy. Subsequent documents will propose ancillary testing recommendations, techniques for cytologic sampling, indications for cytologic study and postcytologic diagnosis management and follow‐up recommendations. Diagn. Cytopathol. 2016;44:399–409. © 2016 Wiley Periodicals, Inc.
Comparative effectiveness and safety of infliximab and adalimumab in patients with ulcerative colitis
Singh, Siddharth , Heien, Herbert C., Sangaralingham, Lindsey R. , Schilz, Stephanie R., Shah, Nilay D. , Loftus, Edward V. , Kappelman, Michael D. , Loftus, Edward V

Alimentary Pharmacology & Therapeutics | March 19, 2016 | Volume: 43 | Issue: 9 | Pages: 994-1003

10.1111/apt.13580 | PMID 26991059 Get It

SummaryBackgroundReal‐world comparative benefits and risks of infliximab (IFX) and adalimumab (ADA) in patients with ulcerative colitis (UC) are unclear.AimTo evaluate the comparative effectiveness and safety of IFX and ADA in patients with UC who were new users of anti‐TNF agents.MethodsUsing an administrative claims database (Optum Labs Data Warehouse), we identified patients who received first anti‐TNF (IFX, ADA) prescription after a 12‐month period without any anti‐TNF treatment (baseline), and with a minimum 6‐month follow‐up after anti‐TNF initiation. Primary outcome measures were: all‐cause and UC‐related hospitalisation, abdominal surgery, corticosteroid use >60 days after starting anti‐TNF, and serious infections. We performed 2:1 propensity‐score matched Cox proportional hazard analysis, and inverse probability‐of‐treatment weight (IPTW) analysis, accounting for healthcare utilisation, comorbidities and use of UC‐related medication.ResultsWe included 1400 new users of anti‐TNF agents (age, 43 ± 15 years; 52% males), from 2006 to 2014. On propensity‐score matched analysis, there was no significant difference in the risk of UC‐related hospitalisation [IFX vs. ADA; adjusted hazard ratio (aHR), 1.04; 95% confidence interval (CI) 0.71–1.51], corticosteroid use (aHR, 0.85; 95% CI, 0.68–1.06) and serious infections (aHR, 0.62; 95% CI, 0.29–1.34) between IFX‐ and ADA‐treated patients; the number of surgical events was very small. On IPTW analysis, risk of corticosteroid use was significantly lower in IFX – as compared to ADA – treated patients (aHR, 0.82; 95% CI, 0.68–0.99). Results were stable on multiple sensitivity analyses.ConclusionsIn a large retrospective cohort of patients with UC who were new users of anti‐TNF agents, IFX‐treated patients may have lower corticosteroid use than ADA‐treated patients, but risk of hospitalisation and serious infections were comparable.
Linkage and related analyses of Barrett's esophagus and its associated adenocarcinomas
Sun, Xiangqing , Elston, Robert C. , Faulx, Ashley L., Shaheen, Nicholas J. , Wang, Jean S. , Iyer, Prasad G. , Guda, Kishore , Markowitz, Sanford D. , Barnholtz‐Sloan, Jill S. , Chandar, Apoorva K., Brock, Wendy , Chak, Amitabh , Falk, Gary W. , Grady, William M. , Mittal, Sumeet K. , Canto, Marcia Irene , Abrams, Julian A , Willis, Joseph , Barnholtz-Sloan, Jill S

Molecular Genetics & Genomic Medicine | March 19, 2016 | Volume: 4 | Issue: 4 | Pages: 407-419

10.1002/mgg3.211 | PMID 27468417 Get It

AbstractBackgroundFamilial aggregation and segregation analysis studies have provided evidence of a genetic basis for esophageal adenocarcinoma (EAC) and its premalignant precursor, Barrett's esophagus (BE). We aim to demonstrate the utility of linkage analysis to identify the genomic regions that might contain the genetic variants that predispose individuals to this complex trait (BE and EAC).MethodsWe genotyped 144 individuals in 42 multiplex pedigrees chosen from 1000 singly ascertained BE/EAC pedigrees, and performed both model‐based and model‐free linkage analyses, using S.A.G.E. and other software. Segregation models were fitted, from the data on both the 42 pedigrees and the 1000 pedigrees, to determine parameters for performing model‐based linkage analysis. Model‐based and model‐free linkage analyses were conducted in two sets of pedigrees: the 42 pedigrees and a subset of 18 pedigrees with female affected members that are expected to be more genetically homogeneous. Genome‐wide associations were also tested in these families.ResultsLinkage analyses on the 42 pedigrees identified several regions consistently suggestive of linkage by different linkage analysis methods on chromosomes 2q31, 12q23, and 4p14. A linkage on 15q26 is the only consistent linkage region identified in the 18 female‐affected pedigrees, in which the linkage signal is higher than in the 42 pedigrees. Other tentative linkage signals are also reported.ConclusionOur linkage study of BE/EAC pedigrees identified linkage regions on chromosomes 2, 4, 12, and 15, with some reported associations located within our linkage peaks. Our linkage results can help prioritize association tests to delineate the genetic determinants underlying susceptibility to BE and EAC.
Transcatheter Tricuspid Valve-in-Valve Implantation for the Treatment of Dysfunctional Surgical Bioprosthetic Valves
McElhinney, Doff B. , Eicken, Andreas , Boudjemline, Younès , Schubert, Stephan , Himbert, Dominique , Asnes, Jeremy D. , Salizzoni, Stefano , Bocks, Martin L. , Momenah, Tarek , Kim, Dennis W. , Schranz, Dietmar, Meadows, Jeffery , Thomson, John , Goldstein, Bryan H. , Crittendon, Ivory, Fagan, Thomas E. , Webb, John G. , Horlick, Eric , Delaney, Jeffrey W., Jones, Thomas K. , Shahanavaz, Shabana , Moretti, Carolina, Hainstock, Michael , Kenny, Damien , Berger, Felix , Rihal, Charanjit S. , Dvir, Danny , Cabalka, Allison K. , Aboulhosn, Jamil A, Cheatham, John P. , Momenah, Tarek S, Thomson, John D R, Hainstock, Michael R, Kenny, Damien P, Aboulhosn, Jamil , Cheatham, John P. , Rihal, Charanjit S. , McElhinney, Doff B , Goldstein, Bryan H

Circulation | March 19, 2016 | Volume: 133 | Issue: 16 | Pages: 1582-1593

10.1161/circulationaha.115.019353 | PMID 26994123 Get It

Background— Off-label use of transcatheter aortic and pulmonary valve prostheses for tricuspid valve-in-valve implantation (TVIV) within dysfunctional surgical tricuspid valve (TV) bioprostheses has been described in small reports. Methods and Results— An international, multicenter registry was developed to collect data on TVIV cases. Patient-related factors, procedural details and outcomes, and follow-up data were analyzed. Valve-in-ring or heterotopic TV implantation procedures were not included. Data were collected on 156 patients with bioprosthetic TV dysfunction who underwent catheterization with planned TVIV. The median age was 40 years, and 71% of patients were in New York Heart Association class III or IV. Among 152 patients in whom TVIV was attempted with a Melody (n=94) or Sapien (n=58) valve, implantation was successful in 150, with few serious complications. After TVIV, both the TV inflow gradient and tricuspid regurgitation grade improved significantly. During follow-up (median, 13.3 months), 22 patients died, 5 within 30 days; all 22 patients were in New York Heart Association class III or IV, and 9 were hospitalized before TVIV. There were 10 TV reinterventions, and 3 other patients had significant recurrent TV dysfunction. At follow-up, 77% of patients were in New York Heart Association class I or II ( P <0.001 versus before TVIV). Outcomes did not differ according to surgical valve size or TVIV valve type. Conclusions— TVIV with commercially available transcatheter prostheses is technically and clinically successful in patients of various ages across a wide range of valve size. Although preimplantation clinical status was associated with outcome, many patients in New York Heart Association class III or IV at baseline improved. TVIV should be considered a viable option for treatment of failing TV bioprostheses.
A Patient with Abnormal Kidney Function and a Monoclonal Light Chain in the Urine
Nasr, Samih H. , Leung, Nelson

Clinical Journal of the American Society of Nephrology | March 18, 2016 | Volume: 11 | Issue: 6 | Pages: 1073-1082

10.2215/cjn.10641015 | PMID 26992418 Get It

Monoclonal gammopathy is increasingly recognized as a cause of kidney injury. These renal conditions behave differently than ones without monoclonal gammopathy and require specific treatment. To avoid misdiagnosis, testing for paraprotein should be performed in addition to vasculitis and autoimmune diseases serologies in adults with unexplained AKI or proteinuria. Because the prevalence of monoclonal gammopathy is much more common than glomerular diseases, the nephrotoxicity of the monoclonal protein must be confirmed before cytotoxic therapy is initiated. This can only be done by a kidney biopsy. After a monoclonal gammopathy of renal significant is verified, the evaluation should then focus on the identification of the pathologic clone, because therapy is clone specific. We present this patient to illustrate the clinical presentation of a patient with renal dysfunction and a monoclonal gammopathy. This patient is also used to discuss the diagnostic process in detail when monoclonal gammopathy–associated renal disease is suspected.
The Impact of Posttraumatic Stress Disorder on the 6-Month Outcomes in Collaborative Care Management for Depression
Angstman, Kurt B. , Marcelin, Alberto, González, César A. , Kaufman, Tara K. , Maxson, Julie, Williams, Mark D. , Maxson, Julie A, Gonzalez, Cesar

Journal of Primary Care & Community Health | March 18, 2016 | Volume: 7 | Issue: 3 | Pages: 159-164

10.1177/2150131916638329 | PMID 26994060 Get It

Posttraumatic stress disorder (PTSD) has symptoms that exist along a spectrum that includes depression and the 2 disorders may coexist. Collaborative care management (CCM) has been successfully used in outpatient mental health management (especially depression and anxiety) with favorable outcomes. Despite this, there exist limited data on clinical impact of a diagnosis of PTSD on depression outcomes in CCM. The present study used a retrospective cohort design to examine the association of PTSD with depression outcomes among 2121 adult patients involved in CCM in a primary care setting. Using standardized self-report measures, baseline depression scores and 6-month outcome scores were evaluated. Seventy-six patients had a diagnosis of PTSD documented in their electronic medical record. Patients with PTSD reported more severe depressive symptoms at baseline (Patient Health Questionnaire–9 score of 17.9 vs 15.4, P < .001) than those without PTSD. Controlling for sociodemographic and clinical characteristics, a clinical diagnosis of PTSD was associated with lower odds (AOR = 0.457, CI = 0.274-0.760, P = .003) of remission at 6 months and was also associated with higher odds (AOR = 3.112, CI = 1.921-5.041, P < .001) of persistent depressive symptoms at 6 months after CCM. When coexisting with depression, a diagnosis of PTSD was associated with worse depression outcomes, when managed with CCM in primary care. Opportunities still exist for more aggressive management of depression in these patients to help improve remission as well as reduce persistent depressive symptoms.
In vitro elimination of gaseous microemboli utilizing hypobaric oxygenation in the Terumo ® FX15 oxygenator
Clingan, Sean , Schuldes, Matthew, Francis, Stephen, Hoerr, Harry R., Riley, Jeff

Perfusion | March 18, 2016 | Volume: 31 | Issue: 7 | Pages: 552-559

10.1177/0267659116638148 | PMID 26993481 Get It

Background: This study examines the efficacy of hypobaric oxygenation as it relates to the elimination of gaseous microemboli (GME) at designated flow, pressure and temperature combinations. Methods: Hypobaric oxygenation was employed for experimental trials (n=60), but not for control trials (n=60), while circuit design, data measurements and testing conditions were maintained for both settings. Hypobaric oxygenation conditions were created by applying 100% oxygen at sub-atmospheric sweep gas pressures of 0.67 atmospheres to the gas phase of an integrated hollow-fiber microporous membrane oxygenator. GME were quantified using an Emboli Detection and Classification system (EDAC), while a continuous air infusion, at a rate of 100 ml/min, was applied to the circuit. Trials were conducted at 37°C, 28°C, and 18°C and at two flow and line pressure combinations of: 3.5 L/min & 150 mmHg and 5 L/min & 200 mmHg. Results: Sub-atmospheric sweep gas pressures allowed adequate oxygenation independent of carbon dioxide removal while significantly reducing the potential entrance of nitrogen into the blood. GME was reduced significantly across all temperatures and flows when compared to control trials; GME counts were reduced by 99.7% post-oxygenator and 99.99% at the arterial cannula. Conclusion: Correlation between the use of hypobaric oxygenation and GME counts suggests hypobaric oxygenation could play a significant role in the reduction of GME.